Literature DB >> 10996442

Suppression of transient 40-Hz auditory response by haloperidol suggests modulation of human selective attention by dopamine D2 receptors.

J Ahveninen1, S Kähkönen, H Tiitinen, E Pekkonen, J Huttunen, S Kaakkola, R J Ilmoniemi, I P Jääskeläinen.   

Abstract

Cognitive processes including selective attention may depend on synchronous activity of neurons at the gamma-band (around 40Hz). To determine the effect of neuroleptic challenge on transient auditory evoked 40-Hz response, simultaneous measurement of 122-channel magnetoencephalogram (MEG) and 64-channel electroencephalogram (EEG) was used. Either 2mg of dopamine D(2)-receptor antagonist haloperidol or a placebo was administered orally to 11healthy subjects in a double-blind randomized crossover design in two separate sessions. The subjects attended to tones presented to one ear and ignored those presented to the other ear. Haloperidol significantly suppressed the transient 40-Hz electric response to the attended stimuli, while no significant effect was observed in the electric responses to the unattended tones or in the magnetic responses. The present result suggests that dopamine D(2) receptors modulate selective attention.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10996442     DOI: 10.1016/s0304-3940(00)01429-4

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  14 in total

1.  Emotion-elicited gamma synchrony in patients with first-episode schizophrenia: a neural correlate of social cognition outcomes.

Authors:  Leanne M Williams; Thomas J Whitford; Marie Nagy; Gary Flynn; Anthony W F Harris; Steven M Silverstein; Evian Gordon
Journal:  J Psychiatry Neurosci       Date:  2009-07       Impact factor: 6.186

2.  Gamma oscillations and schizophrenia.

Authors:  Sylvain Williams; Patricia Boksa
Journal:  J Psychiatry Neurosci       Date:  2010-03       Impact factor: 6.186

3.  Dexamphetamine selectively increases 40 Hz auditory steady state response power to target and nontarget stimuli in healthy humans.

Authors:  Matthew A Albrecht; Greg Price; Joseph Lee; Rajan Iyyalol; Mathew T Martin-Iverson
Journal:  J Psychiatry Neurosci       Date:  2013-01       Impact factor: 6.186

4.  Gamma oscillation deficits and the onset and early progression of schizophrenia.

Authors:  Tsung-Ung W Woo; Kevin Spencer; Robert W McCarley
Journal:  Harv Rev Psychiatry       Date:  2010 May-Jun       Impact factor: 3.732

5.  Acute dopamine depletion with branched chain amino acids decreases auditory top-down event-related potentials in healthy subjects.

Authors:  Andres H Neuhaus; Terry E Goldberg; Youssef Hassoun; John A Bates; Katharine W Nassauer; Serge Sevy; Carolin Opgen-Rhein; Anil K Malhotra
Journal:  Schizophr Res       Date:  2009-04-07       Impact factor: 4.939

6.  Sustained Modafinil Treatment Effects on Control-Related Gamma Oscillatory Power in Schizophrenia.

Authors:  Michael J Minzenberg; Jong H Yoon; Yaoan Cheng; Cameron S Carter
Journal:  Neuropsychopharmacology       Date:  2015-09-02       Impact factor: 7.853

7.  A model for modulation of neuronal synchronization by D4 dopamine receptor-mediated phospholipid methylation.

Authors:  Anna Y Kuznetsova; Richard C Deth
Journal:  J Comput Neurosci       Date:  2007-10-11       Impact factor: 1.621

Review 8.  Neurophysiological biomarkers for drug development in schizophrenia.

Authors:  Daniel C Javitt; Kevin M Spencer; Gunvant K Thaker; Georg Winterer; Mihály Hajós
Journal:  Nat Rev Drug Discov       Date:  2008-01       Impact factor: 84.694

9.  Dynamic oscillatory processes governing cued orienting and allocation of auditory attention.

Authors:  Jyrki Ahveninen; Samantha Huang; John W Belliveau; Wei-Tang Chang; Matti Hämäläinen
Journal:  J Cogn Neurosci       Date:  2013-08-05       Impact factor: 3.225

10.  Neural synchrony in patients with a first episode of schizophrenia: tracking relations with grey matter and symptom profile.

Authors:  Leanne M Williams; Thomas J Whitford; Evian Gordon; Lavier Gomes; Kerri J Brown; Anthony W F Harris
Journal:  J Psychiatry Neurosci       Date:  2009-01       Impact factor: 6.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.